Weskamm Leonie M, Tarnow Paulina, Harms Charlotte, Huchon Melanie, Raadsen Matthijs P, Friedrich Monika, Rübenacker Laura, Grüttner Cordula, Garcia Mariana G, Koch Till, Becker Stephan, Sutter Gerd, Lhomme Edouard, Haagmans Bart L, Fathi Anahita, Blois Sandra M, Dahlke Christine, Richert Laura, Addo Marylyn M
Institute for Infection Research and Vaccine Development (IIRVD), Center for Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
iScience. 2024 Jul 8;27(8):110470. doi: 10.1016/j.isci.2024.110470. eCollection 2024 Aug 16.
Besides neutralizing antibodies, which are considered an important measure for vaccine immunogenicity, Fc-mediated antibody functions can contribute to antibody-mediated protection. They are strongly influenced by structural antibody properties such as subclass and Fc glycan composition. We here applied a systems serology approach to dissect humoral immune responses induced by MVA-MERS-S, an MVA-vectored vaccine against the Middle East respiratory syndrome coronavirus (MERS-CoV). Building on preceding studies reporting the safety and immunogenicity of MVA-MERS-S, our study highlights the potential of a late boost, administered one year after prime, to enhance both neutralizing and Fc-mediated antibody functionality compared to the primary vaccination series. Distinct characteristics were observed for antibodies specific to the MERS-CoV spike protein S1 and S2 subunits, regarding subclass and glycan compositions as well as Fc functionality. These findings highlight the benefit of a late homologous booster vaccination with MVA-MERS-S and may be of interest for the design of future coronavirus vaccines.
除了被视为疫苗免疫原性重要指标的中和抗体外，Fc介导的抗体功能也有助于抗体介导的保护作用。它们受到抗体结构特性（如亚类和Fc聚糖组成）的强烈影响。我们在此应用系统血清学方法剖析由MVA-MERS-S诱导的体液免疫反应，MVA-MERS-S是一种针对中东呼吸综合征冠状病毒（MERS-CoV）的MVA载体疫苗。基于之前报道MVA-MERS-S安全性和免疫原性的研究，我们的研究强调了在初次免疫一年后进行晚期加强免疫的潜力，与初次疫苗接种系列相比，可增强中和抗体和Fc介导的抗体功能。在MERS-CoV刺突蛋白S1和S2亚基特异性抗体的亚类、聚糖组成以及Fc功能方面观察到了不同的特征。这些发现突出了用MVA-MERS-S进行晚期同源加强免疫的益处，可能对未来冠状病毒疫苗的设计具有参考价值。
